Literature DB >> 16702728

Drug-metabolizing ability of molybdenum hydroxylases.

Shigeyuki Kitamura1, Kazumi Sugihara, Shigeru Ohta.   

Abstract

Molybdenum hydroxylases, which include aldehyde oxidase and xanthine oxidoreductase, are involved in the metabolism of some medicines in humans. They exhibit oxidase activity towards various heterocyclic compounds and aldehydes. The liver cytosol of various mammals also exhibits a significant reductase activity toward nitro, sulfoxide, N-oxide and other moieties, catalyzed by aldehyde oxidase. There is considerable variability of aldehyde oxidase activity in liver cytosol of mammals: humans show the highest activity, rats and mice show low activity, and dogs have no detectable activity. On the other hand, xanthine oxidoreductase activity is present widely among species. Interindividual variation of aldehyde oxidase activity is present in humans. Drug-drug interactions associated with aldehyde oxidase and xanthine oxidoreductase are of potential clinical significance. Drug metabolizing ability of molybdenum hydroxylases and the variation of the activity are described in this review.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16702728     DOI: 10.2133/dmpk.21.83

Source DB:  PubMed          Journal:  Drug Metab Pharmacokinet        ISSN: 1347-4367            Impact factor:   3.614


  38 in total

1.  Aldehyde oxidase functions as a superoxide generating NADH oxidase: an important redox regulated pathway of cellular oxygen radical formation.

Authors:  Tapan K Kundu; Murugesan Velayutham; Jay L Zweier
Journal:  Biochemistry       Date:  2012-03-19       Impact factor: 3.162

2.  The impact of single nucleotide polymorphisms on human aldehyde oxidase.

Authors:  Tobias Hartmann; Mineko Terao; Enrico Garattini; Christian Teutloff; Joshua F Alfaro; Jeffrey P Jones; Silke Leimkühler
Journal:  Drug Metab Dispos       Date:  2012-01-25       Impact factor: 3.922

3.  Biomedical Technologies for in vitro Screening and Controlled Delivery of Neuroactive Compounds.

Authors:  John P Frampton; Michael L Shuler; William Shain; Matthew R Hynd
Journal:  Cent Nerv Syst Agents Med Chem       Date:  2008

4.  Discovery of 6-(pyrimidin-5-ylmethyl)quinoline-8-carboxamide negative allosteric modulators of metabotropic glutamate receptor subtype 5.

Authors:  Andrew S Felts; Alice L Rodriguez; Ryan D Morrison; Anna L Blobaum; Frank W Byers; J Scott Daniels; Colleen M Niswender; P Jeffrey Conn; Craig W Lindsley; Kyle A Emmitte
Journal:  Bioorg Med Chem Lett       Date:  2018-04-22       Impact factor: 2.823

5.  Monitoring in vivo metabolism and elimination of the endogenous DNA adduct, M1dG {3-(2-deoxy-beta-D-erythro-pentofuranosyl)pyrimido[1,2-alpha]purin-10(3H)-one}, by accelerator mass spectrometry.

Authors:  Charles G Knutson; Paul L Skipper; Rosa G Liberman; Steven R Tannenbaum; Lawrence J Marnett
Journal:  Chem Res Toxicol       Date:  2008-05-08       Impact factor: 3.739

6.  A novel reaction mediated by human aldehyde oxidase: amide hydrolysis of GDC-0834.

Authors:  Jasleen K Sodhi; Susan Wong; Donald S Kirkpatrick; Lichuan Liu; S Cyrus Khojasteh; Cornelis E C A Hop; John T Barr; Jeffrey P Jones; Jason S Halladay
Journal:  Drug Metab Dispos       Date:  2015-04-06       Impact factor: 3.922

Review 7.  Challenges and Opportunities with Non-CYP Enzymes Aldehyde Oxidase, Carboxylesterase, and UDP-Glucuronosyltransferase: Focus on Reaction Phenotyping and Prediction of Human Clearance.

Authors:  Upendra A Argikar; Philip M Potter; J Matthew Hutzler; Punit H Marathe
Journal:  AAPS J       Date:  2016-08-05       Impact factor: 4.009

8.  Role of Molybdenum-Containing Enzymes in the Biotransformation of the Novel Ghrelin Receptor Inverse Agonist PF-5190457: A Reverse Translational Bed-to-Bench Approach.

Authors:  Sravani Adusumalli; Rohitash Jamwal; R Scott Obach; Tim F Ryder; Lorenzo Leggio; Fatemeh Akhlaghi
Journal:  Drug Metab Dispos       Date:  2019-06-10       Impact factor: 3.922

9.  Structural insights into xenobiotic and inhibitor binding to human aldehyde oxidase.

Authors:  Catarina Coelho; Alessandro Foti; Tobias Hartmann; Teresa Santos-Silva; Silke Leimkühler; Maria João Romão
Journal:  Nat Chem Biol       Date:  2015-08-31       Impact factor: 15.040

10.  Oxidation and glycolytic cleavage of etheno and propano DNA base adducts.

Authors:  Charles G Knutson; Emily H Rubinson; Dapo Akingbade; Carolyn S Anderson; Donald F Stec; Katya V Petrova; Ivan D Kozekov; F Peter Guengerich; Carmelo J Rizzo; Lawrence J Marnett
Journal:  Biochemistry       Date:  2009-02-03       Impact factor: 3.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.